FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2616280353> ?p ?o ?g. }

• W2616280353 endingPage "e0005607" @default.
• W2616280353 startingPage "e0005607" @default.
• W2616280353 abstract "Background Strongyloides seroprevalence is hyper-endemic in many Australian Aboriginal and Torres Strait Islander communities, ranging from 35–60%. We report the impact on Strongyloides seroprevalence after two oral ivermectin mass drug administrations (MDAs) delivered 12 months apart in a remote Australian Aboriginal community. Methods Utilizing a before and after study design, we measured Strongyloides seroprevalence through population census with sequential MDAs at baseline and month 12. Surveys at months 6 and 18 determined changes in serostatus. Serodiagnosis was undertaken by ELISA that used sonicated Strongyloides ratti antigen to detect anti-Strongyloides IgG. Non-pregnant participants weighing ≥15 kg were administered a single 200 μg/kg ivermectin dose, repeated after 10–42 days if Strongyloides and/or scabies was diagnosed; others followed a standard alternative algorithm. A questionnaire on clinical symptoms was administered to identify adverse events from treatment and self-reported symptoms associated with serostatus. Findings We surveyed 1013 participants at the baseline population census and 1060 (n = 700 from baseline cohort and 360 new entrants) at month 12. Strongyloides seroprevalence fell from 21% (175/818) at baseline to 5% at month 6. For participants from the baseline cohort this reduction was sustained at month 12 (34/618, 6%), falling to 2% at month 18 after the second MDA. For new entrants to the cohort at month 12, seroprevalence reduced from 25% (75/297) to 7% at month 18. Strongyloides positive seroconversions for the baseline cohort six months after each MDA were 2.5% (4/157) at month 6 and 1% at month 18, whilst failure to serorevert remained unchanged at 18%. At 12 months, eosinophilia was identified in 59% of baseline seropositive participants and 89% of seropositive new entrants, compared with 47%baseline seronegative participants and 51% seronegative new entrants. Seropositivity was not correlated with haemoglobin or any self-reported clinical symptoms. Clinical symptoms ascertained on the day of treatment and 24–72 hrs after, did not identify any adverse events. Significance Two community ivermectin MDAs delivered 12 months apart by trained Aboriginal researchers in collaboration with non-Indigenous researchers resulted in a sustained and significant reduction in Strongyloides seroprevalence over 18 months. Similar reductions were seen in the baseline cohort and new entrants." @default.
• W2616280353 created "2017-05-26" @default.
• W2616280353 creator A5023976277 @default.
• W2616280353 creator A5029737926 @default.
• W2616280353 creator A5031956134 @default.
• W2616280353 creator A5037170976 @default.
• W2616280353 creator A5055957305 @default.
• W2616280353 creator A5063649007 @default.
• W2616280353 creator A5066311181 @default.
• W2616280353 creator A5067720235 @default.
• W2616280353 creator A5068058892 @default.
• W2616280353 creator A5068619911 @default.
• W2616280353 creator A5069401929 @default.
• W2616280353 creator A5087396651 @default.
• W2616280353 date "2017-05-15" @default.
• W2616280353 modified "2023-10-15" @default.
• W2616280353 title "Strongyloides seroprevalence before and after an ivermectin mass drug administration in a remote Australian Aboriginal community" @default.
• W2616280353 cites W1588155316 @default.
• W2616280353 cites W1961648385 @default.
• W2616280353 cites W1964081449 @default.
• W2616280353 cites W1979464461 @default.
• W2616280353 cites W2001711576 @default.
• W2616280353 cites W2008267530 @default.
• W2616280353 cites W2012573700 @default.
• W2616280353 cites W2014852818 @default.
• W2616280353 cites W2018381343 @default.
• W2616280353 cites W2031874852 @default.
• W2616280353 cites W2032380673 @default.
• W2616280353 cites W2032473557 @default.
• W2616280353 cites W2033678607 @default.
• W2616280353 cites W2040153748 @default.
• W2616280353 cites W2041352234 @default.
• W2616280353 cites W2047040250 @default.
• W2616280353 cites W2065925656 @default.
• W2616280353 cites W2068127938 @default.
• W2616280353 cites W2069407350 @default.
• W2616280353 cites W2071618337 @default.
• W2616280353 cites W2080247557 @default.
• W2616280353 cites W2091965764 @default.
• W2616280353 cites W2101109859 @default.
• W2616280353 cites W2110077385 @default.
• W2616280353 cites W2123303095 @default.
• W2616280353 cites W2130057793 @default.
• W2616280353 cites W2148519771 @default.
• W2616280353 cites W2157816327 @default.
• W2616280353 cites W2165057915 @default.
• W2616280353 cites W2166437412 @default.
• W2616280353 cites W2169379977 @default.
• W2616280353 cites W2283542633 @default.
• W2616280353 cites W230980305 @default.
• W2616280353 cites W2975423009 @default.
• W2616280353 cites W4211036013 @default.
• W2616280353 cites W19350017 @default.
• W2616280353 doi "https://doi.org/10.1371/journal.pntd.0005607" @default.
• W2616280353 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5444847" @default.
• W2616280353 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28505198" @default.
• W2616280353 hasPublicationYear "2017" @default.
• W2616280353 type Work @default.
• W2616280353 sameAs 2616280353 @default.
• W2616280353 citedByCount "43" @default.
• W2616280353 countsByYear W26162803532017 @default.
• W2616280353 countsByYear W26162803532018 @default.
• W2616280353 countsByYear W26162803532019 @default.
• W2616280353 countsByYear W26162803532020 @default.
• W2616280353 countsByYear W26162803532021 @default.
• W2616280353 countsByYear W26162803532022 @default.
• W2616280353 countsByYear W26162803532023 @default.
• W2616280353 crossrefType "journal-article" @default.
• W2616280353 hasAuthorship W2616280353A5023976277 @default.
• W2616280353 hasAuthorship W2616280353A5029737926 @default.
• W2616280353 hasAuthorship W2616280353A5031956134 @default.
• W2616280353 hasAuthorship W2616280353A5037170976 @default.
• W2616280353 hasAuthorship W2616280353A5055957305 @default.
• W2616280353 hasAuthorship W2616280353A5063649007 @default.
• W2616280353 hasAuthorship W2616280353A5066311181 @default.
• W2616280353 hasAuthorship W2616280353A5067720235 @default.
• W2616280353 hasAuthorship W2616280353A5068058892 @default.
• W2616280353 hasAuthorship W2616280353A5068619911 @default.
• W2616280353 hasAuthorship W2616280353A5069401929 @default.
• W2616280353 hasAuthorship W2616280353A5087396651 @default.
• W2616280353 hasBestOaLocation W26162803531 @default.
• W2616280353 hasConcept C126322002 @default.
• W2616280353 hasConcept C142462285 @default.
• W2616280353 hasConcept C159654299 @default.
• W2616280353 hasConcept C165901193 @default.
• W2616280353 hasConcept C203014093 @default.
• W2616280353 hasConcept C2776535787 @default.
• W2616280353 hasConcept C2777499811 @default.
• W2616280353 hasConcept C2778013117 @default.
• W2616280353 hasConcept C2778494684 @default.
• W2616280353 hasConcept C2779300420 @default.
• W2616280353 hasConcept C2780133432 @default.
• W2616280353 hasConcept C2780473561 @default.
• W2616280353 hasConcept C2908647359 @default.
• W2616280353 hasConcept C3013748606 @default.
• W2616280353 hasConcept C42972112 @default.
• W2616280353 hasConcept C45189115 @default.
• W2616280353 hasConcept C71924100 @default.

• next